Trump Fast-Tracks FDA Psychedelics and Marijuana Reviews
Key Questions
What Executive Order is accelerating reviews of psychedelics?
An Executive Order issued on April 18 allocates $50 million to fast-track FDA reviews of psilocybin, MDMA, ibogaine, and LSD for treating PTSD, depression, and veterans' conditions through breakthrough therapy and Right to Try pathways. It involves collaboration between HHS, DEA, and VA, aligning with EO14401's mental health initiatives.
Which psychedelics are targeted for faster approval?
Psilocybin, MDMA, ibogaine, and LSD are being prioritized for PTSD, depression, and veterans' mental health treatments. The initiative uses breakthrough therapy designations and Right to Try provisions to expedite access.
What changes are expected for marijuana restrictions?
The White House is directing federal agencies to prepare for imminent easing of marijuana controls, including a potential downgrade to Schedule III via DEA hearings and an Attorney General announcement. This signals a broader pivot in drug policy amid ongoing details clarification.
How are agencies collaborating on these drug policy shifts?
HHS, DEA, and VA are collaborating to accelerate psychedelic therapies, while the White House pushes DEA and Attorney General actions for marijuana rescheduling. This supports a mental health push under EO14401.
What market impacts have been observed?
Biotech stocks have surged due to the fast-tracking of psychedelics and marijuana policy shifts. Ongoing FDA changes and safety debates continue to influence the sector.
EO (Apr18, $50M) accelerates psilocybin/MDMA/ibogaine/LSD for PTSD/depression/vets via breakthrough/Right to Try, HHS/DEA/VA collab; WH directs imminent marijuana restrictions easing via DEA hearing/AG announcement, broader drug policy pivot. EO14401 mental health push. Biotech surges, ongoing FDA shifts/safety debates.